Reference is made to the stock exchange release from SoftOx Solutions AS (the
"Company") on 13 October 2026 regarding the board resolution to increase the
share capital by carrying out a private placement of NOK 6 440 918,25 under the
financing facility with the investment fund Long State Investments Limited
("Long State").
The new share capital following completion of the private placement has today
been registered with the Norwegian Register of Business Enterprises.
The new share capital of the Company is NOK 54 190 024.96 divided into 2 709 501
248 shares, each with a par value of NOK 0.02.
For more information on the financing facility, please see the Company's stock
exchange release dated 14 September 2025.
For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com
About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
developing SIS (SoftOx Inhalation Solution), a novel inhaled anti-infective
therapy for the treatment of respiratory infections in the airways and lungs.
The Company is listed on Euronext Growth Oslo.
is listed on Euronext Growth Oslo.\